@phdthesis{Moench2017,
  author    = {M{\"o}nch, Romana},
  title     = {The Growth Factor PDGF and its Signaling Pathways in Colorectal Cancer},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-139100},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2017},
  abstract  = {A successful therapy for colorectal cancer (CRC), one of the most common malignancies worldwide, requires the greatest possible research effort. Of critical importance is an understanding of the relevant intracellular networks of signaling cascades, their activation, and the resulting cellular changes that are a prerequisite for a more successful CRC therapy. Vascular endothelial growth factor (VEGF) and the appropriate VEGF receptors represent molecular targets that have already been successfully implemented in the clinic (i.e. using monoclonal antibodies, tyrosine kinase inhibitors). However, for platelet derived growth factor (PDGF) and the relevant PDGF receptors, there are currently no clinically approved molecular therapeutics available. However, there are preliminary data to show that PDGF and its associated signaling pathways play an important role in CRC progression. In particular, the PI3K/Akt/mTOR pathway is emerging as an important intracellular partner of PDGF with which to control proliferation, migration, and angiogenesis in tumor cells. Therefore it was the objective of this work to investigate the multifactorial influence of PDGF on proliferation and metabolism, depending on CRC mutation status. The intention was to identify new therapeutic targets for future cancer therapy through analyses of PDGF-induced intracellular changes. For this purpose two human colorectal cancer cell lines were analyzed at gene and/or protein level for components of the PI3K/Akt/mTOR and MAPK signaling pathway, c-Myc, p53, and HIF1α (hypoxia-inducible-factor 1α). Changes in proliferation and metabolism, either during stimulation with PDGF and/or PI3K/Akt/mTOR inhibition, were also investigated. Experiments conducted at protein level during PDGF stimulation and/or PI3K/Akt/mTOR inhibition revealed changes in signaling pathways and crosstalk. The influence of the tumor suppressors (retinoblastoma, Rb), oncogenes (c-Myc, p53mut), and HIF1α during stimulation with PDGF, and their interactions in the tumor cell with respect to proliferation and glycolysis warrant further examination in terms of clinical treatment options. Investigations at the gene level of ex vivo samples (UICC I-IV) complete the study with regards to the clinical relevance of PDGF. PDGF stimulation increases tumor cell proliferation in HT29 cells via the PI3K/Akt/mTOR pathway rather than the MAPK pathway. However, if the PI3K/Akt/mTOR pathway is pharmacologically blocked, PDGF stimulation is mediated by inhibitory crosstalk through the MAPK pathway. Further analyses revealed that specific Akt inhibition impedes tumor cell growth, while PI3K inhibition had little effect on proliferation. Inhibitory crosstalk was found to be responsible for these different effects. Careful intervention strategies are therefore required if future therapies intend to make use of these specific signaling pathways. One aim of future research should be to gain a better understanding of the crosstalk between these signaling pathways. In this fashion, "over-inhibition" of the signal pathways, which would result in additional clinical side effects for patients, could be prevented. In late stage UICC, more mutation events occur, with tumorigenicity promoted by an increased mutation rate. Given that PDGF is increasingly expressed in the late UICC stages, our data would indicate that PDGF's effects are amplified with increasing malignancy. The activating effect of PDGF on the PI3K/Akt/mTOR pathway and subsequent changes in the activity of p53mut, Rb, c-Myc, and HIF1α, lead to an unfavorable prognosis for colon cancer patients. PDGF acts on colon cancer cells in an Akt-activating, glycolysis-dependent manner. PDGF increases glycolysis and the ability of CRC cells to adjust their energy metabolism. These activities should be taken as possible starting points with which to design therapeutic interventions for CRC therapy. PDGF, as another representative of the growth factor family, seems to play a similar role to VEGF in CRC. The data from this study underline the importance of the PDGF - PI3K/Akt/mTOR pathway-axis and its potential as a possible target in colorectal cancer. Thus PDGF represents an attractive therapeutic target, besides the VEGF/EGFR-based therapies already used in CRC.},
  subject      = {Dickdarmkrebs},
  language  = {en}
}
@phdthesis{Wickert2006,
  author    = {Wickert, Thomas},
  title     = {In vitro-Studien zur Biofunktionalit{\"a}t von Betanin und Indicaxanthin sowie von Extrakten aus der Kaktusfeige (Opuntia ficus indica)},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-19881},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2006},
  abstract  = {Im Fokus dieser Studien standen mit Indicaxanthin und Betanin die beiden wichtigsten Vertreter der Betalaine sowie Kaktusfeigen- (Opuntia ficus indica) Extrakt. Die Durchf{\"u}hrung der Studien erfolgte in folgenden Schritten: - Isolierung der Referenzsubstanzen Betanin und Indicaxanthin sowie Herstellung von Kaktusfeigen-Extrakt und daraus gewonnener Fraktionen, - Untersuchung der Cytotoxizit{\"a}t von Betanin, Indicaxanthin und Kaktusfeigen-Extrakt in humanen permanent Zell-Linien, - Beeinflussung der Apoptose und des Zellzyklus durch Betanin, Indicaxanthin und Kaktusfeigen-Extrakt in humanen permanent Zell-Linien, - Beeinflussung von Enzymen des Fremdstoffmetabolismus durch Betanin, Indica-xanthin und Kaktusfeigen-Extrakt in humanen permanent Zell-Linien. Die Gewinnung von Indicaxanthin (aus Kaktusfeigen), Betanin (aus Rote Beete-Konzentrat) sowie Kaktusfeigen-Extrakt erfolgte anhand literaturbekannter Methoden. Zur Bestimung der Cytotoxizit{\"a}t wurde untersucht, ob die Testsubstanzen die Proliferation von Caco2-, HT29- und HepG2-Zellen hemmen k{\"o}nnen. Als Ergebnis wurden EC50-Werte f{\"u}r die antiproliferative Wirkung von Betanin in Caco2-Zellen sowie f{\"u}r Kaktusfeigen-Extrakt in Caco2-, HT29- und HepG2-Zellen gefunden. Ein Einfluss der Testsubstanzen auf den Zellzyklus von Caco2- und HT29-Zellen wurde nicht beobachtet. Weiterhin induzierten die Testsubstanzen keine Apoptose in Caco2- oder HT29-Zellen. In den Studien zum Fremdstoffmetabolismus wurde beobachtet, dass vor allem Kaktusfeigen-Extrakt den Substratumsatz von Phase II-Enzyme wie UDP-Glucuronosyltransferase und Glutathion-S-Transferase steigern kann.},
  subject      = {Betalaine},
  language  = {de}
}